

#47595

DATE: SEPTEMBER 17, 2020

SUBJECT: ACET1 OPTIONS - EXPIRATION PRICING CONSIDERATION

ACET1 (adjusted Adicet Bio, Inc. options) will be subject to special pricing consideration in expiration processing on September 18, 2020. The pricing consideration is due to the undetermined cash in lieu of fractional shares amount included in the option deliverable of ACET1 as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

## ACET1

ACET1 options are adjusted Adicet Bio, Inc. (formerly resTORbio, Inc.) options, adjusted September 16, 2020 (see OCC Information Memo #47584). The deliverable of ACET1 options is:

**NEW DELIVERABLE** 

PER CONTRACT: 1) 14 Adicet Bio, Inc. (ACET) Common Shares

2) Cash in lieu of approximately 0.2857 fractional ACET Shares

As of September 17, 2020, the ACET Exchange Agent has not determined the price to be used to determine the cash in lieu amount.

For purposes of calculating an ACET1 price for use in expiration processing, OCC will use the following formula:

ACET1 = 0.142857 (ACET)

For example, if ACET closes at 15.40, the ACET1 price would be:

ACET1 = 0.142857 (15.40) = 2.20

This formula includes an estimate for the value of the cash in lieu amount and not the actual amount applicable in the reverse split.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email <a href="mailto:investorservices@theocc.com">investorservices@theocc.com</a>. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email <a href="mailto:memberservices@theocc.com">memberservices@theocc.com</a>.